Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Histiocytic Sarcoma

abstract

  • Further studies need to be performed to examine CD52 expression and function in HS as well as the role of alemtuzumab in a larger cohort of patients. However, the clinical impact of single-agent alemtuzumab in the 2 patients described in this report was very encouraging. Given the toxicity and frequent inefficacy of conventional chemotherapy, patients with incompletely resected HS should be strongly considered for alemtuzumab therapy.

publication date

  • August 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.26712

PubMed ID

  • 22170006

Additional Document Info

start page

  • 3719

end page

  • 24

volume

  • 118

number

  • 15